Balance Sheet
Cash Flow Statement
AmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Chemomab Therapeutics (CMMB) Share-based Compensation (2019 - 2023)

Chemomab Therapeutics posted quarterly Share-based Compensation of $484000.0 for Q1 2023, down 44.62% year-on-year from $874000.0 in Q1 2022, and down 34.59% on a QoQ basis from $740000.0 in Q4 2022.

Chemomab Therapeutics (CMMB) has 5 years of Share-based Compensation data on file, last reported at $484000.0 in Q1 2023.

  • For the quarter ending Q1 2023, Share-based Compensation fell 44.62% year-over-year to $484000.0; the trailing twelve-month figure through Mar 2023 stood at $2.8 million (down 1.02% YoY), and the FY2025 full-year result was $623000.0, up 0.97% from the prior year.
  • Share-based Compensation for Q1 2023 stood at $484000.0, down from $740000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.0 million in Q4 2021 and bottomed at -$357000.0 in Q3 2020.
  • The 5-year median for Share-based Compensation is $380000.0 (2019), against an average of $372882.4.
  • The widest annual swing landed in 2020, when Share-based Compensation plunged 331.82%; it then surged 2954.55% in 2021.
  • A 5-year view of Share-based Compensation shows it stood at $89000.0 in 2019, then tumbled by 62.92% to $33000.0 in 2020, then soared by 2954.55% to $1.0 million in 2021, then dropped by 26.59% to $740000.0 in 2022, then tumbled by 34.59% to $484000.0 in 2023.
  • The last three Share-based Compensation figures came in at $484000.0 (Q1 2023), $740000.0 (Q4 2022), and $836000.0 (Q3 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 892,057.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 305,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 166.40 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 257.40 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 70.15 Mn
10 Chemomab Therapeutics 959.23 Mn 948.86 Mn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2023 484,000.00
Mar 31, 2023 484,000.00
Dec 31, 2022 740,000.00
Dec 31, 2022 740,000.00
Sep 30, 2022 836,000.00
Sep 30, 2022 836,000.00
Jun 30, 2022 761,000.00
Jun 30, 2022 761,000.00
Mar 31, 2022 874,000.00
Mar 31, 2022 874,000.00
Dec 31, 2021 1.01 Mn
Dec 31, 2021 1.01 Mn
Sep 30, 2021 441,000.00
Sep 30, 2021 441,000.00
Jun 30, 2021 527,000.00
Jun 30, 2021 527,000.00
Mar 31, 2021 43,000.00
Mar 31, 2021 43,000.00
Dec 31, 2020 33,000.00
Dec 31, 2020 33,000.00
Sep 30, 2020 -357,000.00
Sep 30, 2020 -357,000.00
Jun 30, 2020 54,000.00
Jun 30, 2020 54,000.00
Mar 31, 2020 46,000.00
Mar 31, 2020 46,000.00
Dec 31, 2019 89,000.00
Dec 31, 2019 89,000.00
Sep 30, 2019 154,000.00
Sep 30, 2019 154,000.00
Jun 30, 2019 226,000.00
Jun 30, 2019 226,000.00
Mar 31, 2019 380,000.00
Mar 31, 2019 380,000.00